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Despite strategies based on social distancing, hygiene, and screening, COVID-19 is progressing
rapidly throughout the world, with healthcare systems at risk of being overwhelmed. While
identification of effective drug therapies is ongoing, vaccines will not be available in the near future.
Therefore, additional preventive strategies are urgently needed.
COVID-19 presents with a spectrum of disease severity, ranging from mild and non-specific flulike symptoms, to pneumonia, and life-threatening complications such as acute respiratory distress
syndrome (ARDS) and multiple organ failure. While transmission of SARS-CoV-2 is thought to
occur mainly via respiratory droplets, the gut may also contribute toward the pathogenesis of
COVID-19 (1). SARS-CoV-2 RNA has been detected in the gastrointestinal tract and stool samples
from patients (2–4), and in sewage systems (5). Coronaviruses, including SARS-Cov-2 can invade
enterocytes, thereby acting as a reservoir for the virus (4). Indeed, large clinical studies from China
indicate that gastrointestinal symptoms are common in COVID-19, and are associated with disease
severity (3, 4).
Probiotics are live microorganisms that when administered in adequate amounts confer a health
benefit on the host (6). Clinical evidence shows that certain probiotic strains help to prevent
bacterial and viral infections, including gastroenteritis, sepsis, and respiratory tract infections
(RTIs). The reason for adding probiotic strains to the overall prevention and care strategy is
founded in science and clinical studies, albeit hitherto none directly on the etiological agent of
this pandemic.

CLINICAL DATA SUPPORTING THE USE OF PROBIOTICS TO
PREVENT COVID-19
Probiotics can prevent antibiotic-associated diarrhea, and infections in the gastrointestinal tract,
but also infections at other sites, including sepsis, and RTIs (7–13). Meta-analyses are the gold
standard for evidence-based medicine. In one analysis of more than 8,000 preterm infants included
in randomized control trials (RCTs), patients receiving enteral supplementation with probiotics
showed a reduction in necrotizing enterocolitis, nosocomial sepsis, and all-cause mortality (14). A
well-conducted RCT including >4,000 newborns in India found a reduction in sepsis and lower
RTIs in infants treated with a strain of Lactobacillus plantarum combined with prebiotics (which
are growth substrates specific for beneficial microorganisms) (15).
Viruses are etiologic agents of over 90% of upper RTIs. The positive impact of probiotics on
prevention of upper RTIs is documented in a number of studies. A meta-analysis of 12 RCTs
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including 3,720 adults and children reported a 2-fold lower
risk of developing upper RTI in subjects taking probiotics,
and a small but significant reduction in disease severity in
those infected. A randomized, double-blind, placebo-controlled
intervention study of 479 adults showed that Lactobacillus gasseri
PA 16/8, Bifidobacterium longum SP 07/3, and Bifidobacterium
bifidum MF 20/5 with vitamins and minerals lowered not only
the duration of common cold episodes but also days with
fever (16). The impact of probiotics on prevention of upper
RTIs caused by specific viruses has also been documented.
An RCT including 94 preterm infants showed that galactooligosaccharide and polydextrose prebiotic mixture (1:1), or
probiotic Lactobacillus rhamnosus GG given between 3 and 60
days of life lowered the incidence of clinically defined virusassociated RTI by 2- to 3-fold compared to placebo (17). The
incidence of rhinovirus-associated episodes, which comprised
80% of all RTIs in this study, was also strongly reduced with
probiotics or prebiotics. The incidence of influenza RTI was
reduced following consumption of Lactobacillus brevis in an
open label study of 1,783 school children (18). Pertinent to the
pandemic affecting adults more than children, these positive
findings were confirmed in an RCT that included 27 elderly
subjects receiving Bifidobacterium longum or placebo (19).
Furthermore, lactic acid bacteria, from which many probiotics
are selected, are part of the upper respiratory tract microbiota
in healthy people, and some strains are being considered for
prevention of recurrent otitis media (20, 21). This makes their
use for contributing to slow down progression of the coronavirus
pandemic worthy of consideration.
Probiotics have also been used to prevent bacterial lower RTIs
in critically ill adults. Meta-analyses of RCTs including close to
2,000 patients found that probiotic strains reduce the incidence

of ventilator-associated pneumonia (22, 23). But low quality of
evidence and conflicting results among different studies calls for
additional well-conducted RCTs.
It should be noted that not all probiotics, even those with
gastrointestinal benefits, necessarily contribute in every way
to reducing the risk of respiratory infection. For example,
Lactobacillus rhamnosus GG and Bifidobacterium animalis ssp.
lactis may contribute to intestinal benefits, but do not reduce the
number of viruses in the nasopharynx (24). Examples of products
that could be considered, depending on availability in a given
country, are provided in Table 1.

MECHANISTIC BASIS FOR THE ACTION
OF PROBIOTICS TO PREVENT
INFECTIONS AND RELEVANCE TO
COVID-19
Mechanisms that might explain clinical success of probiotics
include enhancement of the intestinal epithelial barrier,
competition with pathogens for nutrients and adhesion to the
intestinal epithelium, production of anti-microbial substances
and modulation of the host immune system (28). An RCT of 55
infants showed that enteral supplementation with a combination
of Bifidobacterium bifidum and Streptococcus thermophilus
reduced the incidence of diarrhea and shedding of rotaviruses
(29), an effect that has been confirmed in subsequent studies
(30). This would indicate interference with viral entry into cells
and/or inhibition of viral replication in the intestine. While
this mechanism may have a role in reducing dissemination
of coronavirus via the gut, the probiotic strains were not
administered to the respiratory tract. So, direct inhibition may

TABLE 1 | The following are examples (not exclusive) of probiotic products, or web sites listing products, with documentation in human studies that may have relevance
to reducing the burden of the coronavirus pandemic.
Products

Basis for inclusion

When to administer

References

Lactobacillus casei DN-114 001; DanActive/Actimel
Fermented drink, Danone

Reduced incidence and duration of RTIs

Once daily for duration of the pandemic

(12, 13)

Lactobacillus gasseri PA 16/8, Bifidobacterium
longum SP 07/3, and B. bifidum MF 20/5; Tribion
harmonis, Merck

Lowering duration and severity of flu-like
illness

Once daily for duration of the pandemic

(16)

Lactobacillus rhamnosus GG; Culturelle or other
brand names

For digestive health and gut barrier
integrity, and prevention of viral RTIs

One capsule daily for duration of the
pandemic

(17)

Lactobacillus plantarum DR7; Malaysia

Prevention of upper RTIs, immune
modulation

2 g sachet per day for duration of
pandemic

(25)

Bifidobacterium breve Yakult, and Lactobacillus
casei Shirota; available as fermented drinks

Lower incidence of ventilator-associated
pneumonia

One of each day for duration of the
pandemic

(26)

Bifidobacterium longum BB536; Morinaga, and sold
in many formulations

Enhances innate immunity, prevents
influenza infection

One each day for duration of the pandemic

(19)

Pediococcus pentosaceus 5-33:3, Leuconostoc
mesenteroides 32-77:1, L. paracasei ssp. paracasei
19, L. plantarum 2,362 plus inulin, oat bran, pectin,
and resistant starch; Medipharm, Sweden

To reduce rate of SIRS, infections, sepsis,
days of stay in the intensive care unit, days
under mechanical ventilation, and mortality

For COVID-19 patients

(27)

A list of probiotics available in Canada for various health issues; www.probioticchart.ca
A list of probiotics available in the USA for various health issues; www.usprobioticguide.com
We must emphasize that none have been tested or proven to have an effect against SARS-CoV2, the virus causing COVID-19, nor are they proven treatments or cures for this condition.
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appear impossible at this site. Having said that, lungs have
their own microbiota and a gut-lung connection has been
described whereby host-microbe, microbe-microbe and immune
interactions can influence the course of respiratory diseases (31).
RTIs such as influenza are associated with an imbalance in the
microbial communities of the respiratory and gastrointestinal
tracts (32, 33). This dysbiosis may alter subsequent immune
function and predispose to secondary bacterial infection. As
reports from China indicate that COVID-19 might be associated
with intestinal dysbiosis causing inflammation and poorer
response to pathogens (34, 35), the case exists for probiotic
strains that restore gut homeostasis (36). It is feasible that
orally administered probiotic strains could further influence this
gut-lung axis, as some can migrate from the gut to distant sites,
such as the breast to treat mastitis (37).
The gut microbiome has a critical impact on systemic
immune responses, and immune responses at distant mucosal
sites, including the lungs (38, 39). Administration of certain
bifidobacteria or lactobacilli has beneficial impact on influenza
virus clearance from the respiratory tract (39, 40). Probiotic
strains improve levels of type I interferons, increase the
number and activity of antigen presenting cells, NK cells, T
cells, as well as the levels of systemic and mucosal specific
antibodies in the lungs (16, 19, 39). There is also evidence
that probiotic strains modify the dynamic balance between
proinflammatory and immunoregulatory cytokines that allow
viral clearance while minimizing immune response-mediated
damage to the lungs. This might be particularly relevant to
prevent ARDS, a major complication of COVID-19. An RCT
with Lactobacillus plantarum DR7 showed suppression of plasma
pro-inflammatory cytokines (IFN-γ, TNF-α) in middle-aged
adults, and enhancement of anti-inflammatory cytokines (IL-4,
IL-10) in young adults, along with reduced plasma peroxidation
and oxidative stress levels (25). Given the cytokine storm that
appears to occur in many COVID-19 patients, this type of
modulation may prove to be very important. The manner in
which orally administered probiotic strains contributes to this
appears to involve the immune response emanating from the
intestine, a focal point of the body’s defenses. Therefore, probiotic
strains documented to enhance the integrity of tight junctions,
for example through increasing butyrate, a fuel for colonocytes
could theoretically reduce SARS-Cov-2 invasion.
Evidence for antiviral activity of probiotic strains against
common respiratory viruses, including influenza, rhinovirus, and
respiratory syncytial virus comes from clinical and experimental
studies (17–19, 41). While none of these effects or mechanisms
have been tested on the new SARS-CoV-2 virus, this should
not negate considering this approach, especially when effects of
probiotics against other coronavirus strains have been reported
(42–45). Furthermore, patients are dying from secondary
bacterial infections. A recent study in mice has shown that oral

administration of Lactobacillus acidophilus CMCC878, started
24 h after pulmonary inoculation of Pseudomonas aeruginosa and
Staphylococcus aureus reduced bacterial load in the lungs, and
decreased lung damage and systemic inflammation (46).

SAFETY OF PROBIOTICS
Probiotics are generally safe, even in the most vulnerable
populations and in intensive care settings (14, 47). Cases
of probiotic-associated bacteremia and fungaemia have
occurred on extremely rare occasions, mainly in premature
and immunocompromised patients treated with preparations
lacking adequate quality control (48, 49). Rather than consider
intensive care patients too ill to receive probiotic and prebiotic
therapy, RCTs of probiotics for the prevention of ventilatorassociated pneumonia provide a reason to consider them
(22, 23, 26). Moreover, in an RCT of 65 critically ill, mechanically
ventilated, multiple trauma patients, the synbiotic Pediococcus
pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, L.
paracasei ssp. paracasei 19, L. plantarum 2,362 plus inulin, oat
bran, pectin, and resistant starch resulted in reduced rate of
infections, systemic inflammatory response syndrome, sepsis,
days of stay in the intensive care unit, days under mechanical
ventilation, and mortality (27).

SUMMARY
In summary, orally administered probiotic strains can reduce
the incidence and severity of viral RTIs. At a time when
doctors are using drugs with little anti- COVID-19 data,
probiotic strains documented for anti-viral and respiratory
activities (not low-quality undocumented imitations) should
become part of the armamentarium to reduce the burden
and severity of this pandemic. Government funding is being
used to test numerous drugs but just as important, they
should fund probiotic trials. In addition, use of recognized
prebiotics (e.g., fructans, galactans) to enhance propagation of
probiotic strains and indigenous beneficial microbes should
be recommended as part of the overall strategy to flatten the
curve (11, 50).
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